Cargando…

The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma

PURPOSE: Conjunctival squamous cell carcinoma (SCC) is a sight-threatening ocular surface malignancy with the primary treatment modality being surgical resection. To evaluate surgical imaging modalities to improve surgical resection, we established a novel murine model for conjunctival SCC to demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Youn, Gun Min, Case, Ayden G., Jarin, Trent, Li, BaoXiang, Swarup, Aditi, Naranjo, Andrea, Bou-Khalil, Charbel, Yao, Jacqueline, Zhou, Quan, Hom, Marisa E., Rosenthal, Eben L., Wu, Albert Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344218/
https://www.ncbi.nlm.nih.gov/pubmed/35895055
http://dx.doi.org/10.1167/tvst.11.7.23
_version_ 1784761170807226368
author Youn, Gun Min
Case, Ayden G.
Jarin, Trent
Li, BaoXiang
Swarup, Aditi
Naranjo, Andrea
Bou-Khalil, Charbel
Yao, Jacqueline
Zhou, Quan
Hom, Marisa E.
Rosenthal, Eben L.
Wu, Albert Y.
author_facet Youn, Gun Min
Case, Ayden G.
Jarin, Trent
Li, BaoXiang
Swarup, Aditi
Naranjo, Andrea
Bou-Khalil, Charbel
Yao, Jacqueline
Zhou, Quan
Hom, Marisa E.
Rosenthal, Eben L.
Wu, Albert Y.
author_sort Youn, Gun Min
collection PubMed
description PURPOSE: Conjunctival squamous cell carcinoma (SCC) is a sight-threatening ocular surface malignancy with the primary treatment modality being surgical resection. To evaluate surgical imaging modalities to improve surgical resection, we established a novel murine model for conjunctival SCC to demonstrate the utility of panitumumab-IRDye800, a fluorescently labeled anti-epidermal growth factor receptor (EGFR) antibody. METHODS: NOD-scid IL2Rgamma(null) (NSG) mice received subconjunctival injection of UM-SCC-1 or SCC-9, head and neck SCC cell lines. On tumor growth, mice were injected with Panitumumab-IRDye800CW, and imaged with a small animal imaging system and optical coherence tomography (OCT). Immunohistochemistry for SCC markers were used to confirm tumor origin. RESULTS: Seventy-five percent (N = 4) of the UM-SCC-1 group developed aggressive, rapidly growing tumors that were P40 and EGFR positive within two weeks of inoculation. The SCC-9 tumors failed to demonstrate any growth (N = 4). Ocular tumors demonstrated high fluorescence levels with a tumor to background ratio of 3.8. CONCLUSIONS: Subconjunctival injections are an appropriate technique to create in vivo models for assessing treatment modalities and novel therapies in conjunctival SCC. TRANSLATIONAL RELEVANCE: This model demonstrates Panitumumab-IRDye800CW's utility in the ophthalmic setting and suggests that clinical trials may be warranted.
format Online
Article
Text
id pubmed-9344218
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Association for Research in Vision and Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-93442182022-08-03 The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma Youn, Gun Min Case, Ayden G. Jarin, Trent Li, BaoXiang Swarup, Aditi Naranjo, Andrea Bou-Khalil, Charbel Yao, Jacqueline Zhou, Quan Hom, Marisa E. Rosenthal, Eben L. Wu, Albert Y. Transl Vis Sci Technol Ocular Oncology PURPOSE: Conjunctival squamous cell carcinoma (SCC) is a sight-threatening ocular surface malignancy with the primary treatment modality being surgical resection. To evaluate surgical imaging modalities to improve surgical resection, we established a novel murine model for conjunctival SCC to demonstrate the utility of panitumumab-IRDye800, a fluorescently labeled anti-epidermal growth factor receptor (EGFR) antibody. METHODS: NOD-scid IL2Rgamma(null) (NSG) mice received subconjunctival injection of UM-SCC-1 or SCC-9, head and neck SCC cell lines. On tumor growth, mice were injected with Panitumumab-IRDye800CW, and imaged with a small animal imaging system and optical coherence tomography (OCT). Immunohistochemistry for SCC markers were used to confirm tumor origin. RESULTS: Seventy-five percent (N = 4) of the UM-SCC-1 group developed aggressive, rapidly growing tumors that were P40 and EGFR positive within two weeks of inoculation. The SCC-9 tumors failed to demonstrate any growth (N = 4). Ocular tumors demonstrated high fluorescence levels with a tumor to background ratio of 3.8. CONCLUSIONS: Subconjunctival injections are an appropriate technique to create in vivo models for assessing treatment modalities and novel therapies in conjunctival SCC. TRANSLATIONAL RELEVANCE: This model demonstrates Panitumumab-IRDye800CW's utility in the ophthalmic setting and suggests that clinical trials may be warranted. The Association for Research in Vision and Ophthalmology 2022-07-27 /pmc/articles/PMC9344218/ /pubmed/35895055 http://dx.doi.org/10.1167/tvst.11.7.23 Text en Copyright 2022 The Authors https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License.
spellingShingle Ocular Oncology
Youn, Gun Min
Case, Ayden G.
Jarin, Trent
Li, BaoXiang
Swarup, Aditi
Naranjo, Andrea
Bou-Khalil, Charbel
Yao, Jacqueline
Zhou, Quan
Hom, Marisa E.
Rosenthal, Eben L.
Wu, Albert Y.
The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma
title The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma
title_full The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma
title_fullStr The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma
title_full_unstemmed The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma
title_short The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma
title_sort use of panitumumab-irdye800cw in a novel murine model for conjunctival squamous cell carcinoma
topic Ocular Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344218/
https://www.ncbi.nlm.nih.gov/pubmed/35895055
http://dx.doi.org/10.1167/tvst.11.7.23
work_keys_str_mv AT youngunmin theuseofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT caseaydeng theuseofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT jarintrent theuseofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT libaoxiang theuseofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT swarupaditi theuseofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT naranjoandrea theuseofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT boukhalilcharbel theuseofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT yaojacqueline theuseofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT zhouquan theuseofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT hommarisae theuseofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT rosenthalebenl theuseofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT wualberty theuseofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT youngunmin useofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT caseaydeng useofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT jarintrent useofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT libaoxiang useofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT swarupaditi useofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT naranjoandrea useofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT boukhalilcharbel useofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT yaojacqueline useofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT zhouquan useofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT hommarisae useofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT rosenthalebenl useofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma
AT wualberty useofpanitumumabirdye800cwinanovelmurinemodelforconjunctivalsquamouscellcarcinoma